[go: up one dir, main page]

BRPI0517646A - compostos de aril pirimidila, composições farmacêuticas compreendendo os mesmos, seu uso como agentes antimicrobianos - Google Patents

compostos de aril pirimidila, composições farmacêuticas compreendendo os mesmos, seu uso como agentes antimicrobianos

Info

Publication number
BRPI0517646A
BRPI0517646A BRPI0517646-8A BRPI0517646A BRPI0517646A BR PI0517646 A BRPI0517646 A BR PI0517646A BR PI0517646 A BRPI0517646 A BR PI0517646A BR PI0517646 A BRPI0517646 A BR PI0517646A
Authority
BR
Brazil
Prior art keywords
aryl
pharmaceutical compositions
antimicrobial agents
pyrimidyl compounds
pyrimidyl
Prior art date
Application number
BRPI0517646-8A
Other languages
English (en)
Inventor
Dominique Douguet
Gilles Labesse
Sylvie Pochet
Helene Munierlehmann
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of BRPI0517646A publication Critical patent/BRPI0517646A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS DE ARIL PIRIMIDILA, COMPOSIçõES FARMACêUTICAS COMPREENDENDO OS MESMOS, SEU USO COMO AGENTES ANTIMICROBIANOS. Compostos de aril pirimidila substituidos correspondendo à fórmula (I) e seu uso para a preparação de um medicamento para a prevenção e/ou tratamento de uma patologia causada por uma micobactéria.
BRPI0517646-8A 2004-11-05 2005-11-04 compostos de aril pirimidila, composições farmacêuticas compreendendo os mesmos, seu uso como agentes antimicrobianos BRPI0517646A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292629A EP1655288A1 (en) 2004-11-05 2004-11-05 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
PCT/EP2005/012346 WO2006048336A2 (en) 2004-11-05 2005-11-04 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents

Publications (1)

Publication Number Publication Date
BRPI0517646A true BRPI0517646A (pt) 2008-10-14

Family

ID=34931507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517646-8A BRPI0517646A (pt) 2004-11-05 2005-11-04 compostos de aril pirimidila, composições farmacêuticas compreendendo os mesmos, seu uso como agentes antimicrobianos

Country Status (7)

Country Link
US (1) US20080096907A1 (pt)
EP (2) EP1655288A1 (pt)
JP (1) JP2008519001A (pt)
CN (1) CN101098860A (pt)
BR (1) BRPI0517646A (pt)
CA (1) CA2586073A1 (pt)
WO (1) WO2006048336A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI445696B (zh) * 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
RU2475482C1 (ru) * 2012-01-13 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение 5-гидрокси-6-метилурацила с сукцинатом натрия и способ его получения
PT3432887T (pt) * 2016-03-22 2020-12-04 Glaxosmithkline Ip Dev Ltd Agente antituberculose
US20220041627A1 (en) * 2018-12-04 2022-02-10 University Of Maryland, Baltimore Prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959705A1 (de) * 1969-11-28 1971-06-03 Bayer Ag Verfahren zur Herstellung von Uracilderivaten
JPH08325238A (ja) * 1995-05-30 1996-12-10 Asahi Glass Co Ltd ５−トリフルオロメチルウラシル誘導体およびその製造方法
ATE201016T1 (de) * 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
KR100814269B1 (ko) * 2000-01-25 2008-03-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀-분비 호르몬 수용체 길항제 및 이를 포함하는 약제학적 조성물
CA2436665C (en) * 2001-01-29 2012-01-10 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2006048336A3 (en) 2006-10-12
CN101098860A (zh) 2008-01-02
CA2586073A1 (en) 2006-05-11
EP1655288A1 (en) 2006-05-10
WO2006048336B1 (en) 2006-11-09
JP2008519001A (ja) 2008-06-05
EP1814867A2 (en) 2007-08-08
WO2006048336A2 (en) 2006-05-11
US20080096907A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0821855B8 (pt) composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0619153B8 (pt) derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
ECSP088102A (es) Compuestos para el tratamiento de infecciones bacterianas resistentes a múltiples fármacos
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
DK2150530T3 (da) Substituerede sulfonamid-derivater
BR112013017316A2 (pt) compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
UY30759A1 (es) Compuestos quimicos
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
MX389142B (es) Compuestos espiro triciclicos.
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
BRPI0923326A2 (pt) Composto, composição farmacêutica, métodos para inibir girasse de dna bacteriana e/ou topisomerase iv bacteriana, para produzir um efeito antibacteriano em um animal de sangue quente, e para tratar uma infecção bacteriana, uso de um composto, e, processo para preparar um composto.
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
BRPI0616944B8 (pt) compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem
BRPI0511874A (pt) derivados da pirrolopiridina
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BRPI0509912A (pt) compostos, processo para a preparação dos mesmos, composição farmacêutica, e, uso de um composto
BRPI0616111B8 (pt) derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.